Another Raltegravir Switch Study, Different Outcome

In the SPIRAL study, switching virologically controlled patients from a protease inhibitor to raltegravir was associated with noninferior efficacy and favorable lipid-profile changes.

Boosted protease inhibitors (PIs) are a highly effective component of many modern antiretroviral regimens, but they can interact with numerous drugs and are associated with various adverse effects, most notably metabolic events. In the SPIRAL study, investigators explored (yet again) whether patients with virologic suppression on boosted PIs can safely switch to raltegravir.

The multicenter, open-label trial (partially sponsored by the maker of raltegravir) involved 273 patients on boosted PI–based regimens who had viral loads <50 copies/mL for at least 6 months; 139 were randomized to switch to raltegravir, and 134 continued their PIs.

At 48 weeks, 89.2% of the raltegravir group and 86.6% of the PI group had not experienced treatment failure…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Another Raltegravir Switch Study, Different Outcome

Topics

Reviewing Author